Novartis denies problems with swine flu vaccine

Oct 26, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

The vaccine, branded as Celtura, is produced by a technique using cell cultures from dog kidneys, allowing more rapid production than by the more classical method using chicken eggs, according to the company.

Citing anonymous sources close to the case, the Swiss daily Tages-Anzeiger reported on Saturday that the Swiss authority overseeing medicines and therapeutical products, Swissmedic, had found in test batches of Celtura.

A spokesman at Swissmedic told AFP that the agency could "neither confirm nor deny" the report.

Swissmedic is due to give its authorisation for the vaccine this week ahead of a mass vaccination campaign against influenza A(H1N1) in Switzerland.

A spokesman for Novartis, Eric Althoff, insisted on Monday that the Celtura vaccine was not contaminated.

"There is no contamination of Celtura, the process is much cleaner than by chicken eggs," he told AFP.

Novartis is hoping for the green light to market the vaccine from Swiss health authorities in the coming days and from the European Union in the next few weeks.

The spokesman insisted that the production process was the same as that which has been used on a seasonal flu vaccine for several years.

About 8,000 people have taken part in clinical trials of A(H1N1) vaccines, he added.

Novartis already markets another swine in Europe under the brand name Focetria, which is based on chicken egg cultures.

(c) 2009 AFP

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

Novartis starts testing swine flu vaccine

Aug 05, 2009

(AP) -- Swiss drugmaker Novartis has begun injecting its swine flu vaccine into people in the company's first human tests, a spokesman said Wednesday. The vaccine is being tested in a yearlong trial of 6,000 ...

US company makes first batch of swine flu vaccine

Jun 24, 2009

A US company that on Tuesday was awarded a 35-million-dollar contract to develop an influenza vaccine using insect cell technology has produced a first batch against (A)H1N1 flu, company boss Dan Adams said.

WHO: Swine flu vaccine on track

Aug 06, 2009

(AP) -- Swine flu vaccine manufacturers are on track to start delivering the first batches of it in September, the World Health Organization said Thursday.

Sanofi to deliver swine flu vaccine in October

Sep 21, 2009

(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

19 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0